epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2020-19-2-110-118epidemiology-990Research ArticleОБЗОРREVIEWДостижения и перспективы вакцинопрофилактики папилломовирусной инфекции и ассоциированных заболеванийAchievements and Prospects of Vaccination against Human Papillomavirus Infection and Associated DiseasesМинкинаГ. Н.MinkinaG. N.

Минкина Галина Николаевна − доктор медицинских наук, профессор кафедры акушерства и гинекологии

127473 Россия, Москва, ул. Делегатская 20/1

Galina N. Minkina − Dr. Sci. (Med.), Professor of the Department of Obstetrics and Gynecology

Delegatskaya st. 20/1, Moscow, 127473

minkinagn@mail.ruФГБОУ ВО Московский государственный медико-стоматологический университет им. А. И. Евдокимова Минздрава РоссииРоссияMoscow State University of Medicine and Dentistry named after AI EvdakimovRussian Federation202016052020192110118Copyright © Минкина Г.Н., 20202020Минкина Г.Н.Minkina G.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/990Актуальность

Актуальность. Прошедшее десятилетие ознаменовано стремительными достижениями в области профилактики инфекций, вызываемых вирусом папилломы человека (ВПЧ) и ассоциированных заболеваний.

Цель

Цель. В обзоре обобщен многолетний мировой опыт и рассмотрена доказательная база влияния национальных программ вакцинации против ВПЧ на распространенность ВПЧ-инфекции, заболеваемость генитальными кондиломами и предраковыми цервикальными поражениями в клинической практике. Представлены результаты модельных исследований эффективности различных стратегий вакцинации для создания коллективного иммунитета, гендерно-нейтральной вакцинации и потенциала для элиминации онкогенных типов ВПЧ.

Вывод

Вывод. Ликвидация ВПЧ-ассоциированных раков и, прежде всего, рака шейки матки, теперь является реалистичной перспективой.

Relevance

Relevance. The past decade has been marked by rapid advances in the prevention of human papillomavirus (HPV) infections and associated diseases.

Aims

Aims. To sum up the accumulated experience and evidence base of the impact of national HPV vaccination programs on the prevalence of HPV infections, the incidence of genital warts and precancerous cervical lesions. 3.

Conclusions

Conclusions. To reach its full potential and have a greater and earlier impact on the population, gender-neutral and, if possible, multi-cohort HPV vaccination should be included in the national immunization calendar.

ВПЧвакцинациягенитальные кондиломыCINцервикальный ракHPVvaccinationgenital wartsCINcervical cancerReferencesWHO. Human papillomavirus (HPV) and cervical cancer, 24.01.2019. Доступно на: https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancerWHO. Human papillomavirus (HPV) and cervical cancer, 24.01.2019. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancerBruni L. The frequency of HPV infection worldwide. HPVWorld. March 2018, Year 2 Nº 35. Доступно на: https://www.hpvworld.com.Bruni L. The frequency of HPV infection worldwide. HPVWorld. March 2018, Year 2 Nº 35. Available at: https://www.hpvworld.com/de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15; 141(4): 664−670. doi: 10.1002/ijc.30716.de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15; 141(4): 664−670. doi: 10.1002/ijc.30716.Serrano B, Brotons M, Bosch FX, et al.. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47: 14−26. doi: 10.1016/j.bpobgyn.2017.08.006.Serrano B, Brotons M, Bosch FX, et al.. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47: 14−26. doi: 10.1016/j.bpobgyn.2017.08.006.de Sanjosé, S. Tsu V.D. Spectrum of HPV related diseases. HPVWorld. March 2018, Year 2 Nº 36. Доступно на: https://www.hpvworld.com.de Sanjosé, S. Tsu V.D. Spectrum of HPV related diseases. HPVWorld. March 2018, Year 2 Nº 36. Available at: https://www.hpvworld.com/Bruni L, Albero G, Serrano B et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Russian Federation. Summary Report 10 December 2018. Доступно на: https://hpvcentre.net/index.php.Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Russian Federation. Summary Report 10 December 2018. Available at: https://hpvcentre.net/index.php.Грецова О. П., Костин А. А., Самсонов Ю. В. и др. Заболеваемость и смертность от злокачественных новообразований, ассоциированных с вирусом папилломы человека. Исследования и практика в медицине 2017; 4(3): 33 −50. https://doi.org/10.17709/2409-2231-2017-4-3-4.Gretsova O.P., Kostin A.A., Samsonov Y.V. et al. Morbidity and mortality from malignant neoplasms associated with human papillomavirus. Research’n Practical Medicine Journal. 2017; 4(3): 33−50 (In Russ.). https://doi.org/10.17709/2409-2231-2017-4-3-4].Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Каприн А. Д., Старинский В. В., Петрова Г. В., ред. М.: МНИОИ им. П. А. Герцена − филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 250 с..Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed.: Kaprin A.D., Starinsky V.V., Petrova G.V. Moscow: MNIOI im. P.A. Herzen - branch of the NWIRTC of the Ministry of Health of Russia; 2018: 250 (in Russ.).WHO. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017 Oct 13;35(43):5753-5755. doi: 10.1016/j.vaccine.2017.05.069. Доступно на: http://www.who.int/wer.WHO. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017 Oct 13; 35(43): 5753−5755. doi: 10.1016/j.vaccine.2017.05.069. Available at: http://www.who.int/wer.Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018. May 9; 5:CD009069.Arbyn M., Xu L., Simoens C. et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018. May 9; 5:CD009069.Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3; 364(5): 401−11. doi: 10.1056/NEJMoa0909537.Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011 Feb 3; 364(5): 401−11. doi: 10.1056/NEJMoa0909537.WHO. Vaccine in National Immunization Programme Update January 2020. Доступно на: https://www.who.int/immunization/monitoring_surveillance/en.WHO. Vaccine in National Immunization Programme Update January 2020. Available at: https://www.who.int/immunization/monitoring_surveillance/en.Garland S.M., Kjaer S.K., Muñoz N. et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15; 63(4): 519−27. doi: 10.1093/cid/ciw354.Garland S.M., Kjaer S.K., Muñoz N. et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15; 63(4): 519−27. doi: 10.1093/cid/ciw354.Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018 Aug 28; 36(36): 5416−5423. doi: 10.1016/j.vaccine.2017.07.113.Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018 Aug 28; 36(36): 5416−5423. doi: 10.1016/j.vaccine.2017.07.113.Patel C., Brotherton J.M., Pillsbury A. et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018 Oct; 23(41). doi: 10.2807/1560-7917.ES.2018.23.41.1700737.Patel C., Brotherton J.M., Pillsbury A. et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018 Oct; 23(41). doi: 10.2807/1560-7917.ES.2018.23.41.1700737.Department of Health and Ageing. Immunise Australia program: human papillomavirus (HPV). February 14, 2013. Доступно на: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.Department of Health and Ageing. Immunise Australia program: human papillomavirus (HPV). February 14, 2013. Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.The National Human Papillomavirus (HPV) Vaccination Program Register. Доступно на: http://www.hpvregister.org.au/research/coverage-data.The National Human Papillomavirus (HPV) Vaccination Program Register. Available at: http://www.hpvregister.org.au/research/coverage-data.Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5.Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5.Machalek DA, Garland SM, Brotherton JML et al. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. J Infect Dis. 2018 Apr 23;217(10):1590-1600. doi: 10.1093/infdis/jiy075.Machalek DA, Garland SM, Brotherton JML et al. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. J Infect Dis. 2018 Apr 23;217(10):1590-1600. doi: 10.1093/infdis/jiy075.Chow EPF, Machalek DA, Tabrizi SN et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017 Jan; 17(1): 68−77. doi: 10.1016/S1473-3099(16)30116-5.Chow EPF, Machalek DA, Tabrizi SN et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017 Jan; 17(1): 68−77. doi: 10.1016/S1473-3099(16)30116-5.Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015 May; 15(5): 565 −80. doi: 10.1016/S1473-3099(14)71073-4.Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015 May; 15(5): 565 −80. doi: 10.1016/S1473-3099(14)71073-4.Drolet M, Laprise JF, Brotherton JML et al. The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. J Infect Dis. 2017 Dec 5; 216(10): 1205−1209. doi: 10.1093/infdis/jix476.Drolet M, Laprise JF, Brotherton JML et al. The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. J Infect Dis. 2017 Dec 5; 216(10): 1205−1209. doi: 10.1093/infdis/jix476.Read TRH, Hocking JS, Chen MY et al.. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011; 87(7): 544−7. https://doi.org/10.1136/sextrans-2011-050234.Read TRH, Hocking JS, Chen MY et al.. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011; 87(7): 544−7. https://doi.org/10.1136/sextrans-2011-050234.Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346(apr181):f2032. https://doi.org/10.1136/bmj.f2032.Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013; 346(apr181):f2032. https://doi.org/10.1136/bmj.f2032.Chow EPF, Read TRH, Wigan R et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015; 91(3): 214−9. https://doi.org/10.1136/sextrans-2014-051813.Chow EPF, Read TRH, Wigan R et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015; 91(3): 214−9. https://doi.org/10.1136/sextrans-2014-051813.Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015 Jan 1; 211(1): 91 −9. doi: 10.1093/infdis/jiu370.Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 2015 Jan 1; 211(1): 91 −9. doi: 10.1093/infdis/jiu370.Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Доступно на: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf.Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf.Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348(mar04 2):g1458. https://doi.org/10.1136/bmj.g1458.Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348(mar04 2):g1458. https://doi.org/10.1136/bmj.g1458.Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013; 11(1): 227. https://doi.org/10.1186/1741-7015-11-227.Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013; 11(1): 227. https://doi.org/10.1186/1741-7015-11-227.Ogilvie GS, Naus M, Money DM et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015 Oct 15; 137(8): 1931−7. doi: 10.1002/ijc.29508.Ogilvie GS, Naus M, Money DM et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015 Oct 15; 137(8): 1931−7. doi: 10.1002/ijc.29508.Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016 Jun 15; 138(12): 2867−74. doi: 10.1002/ijc.30035.Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016 Jun 15; 138(12): 2867−74. doi: 10.1002/ijc.30035.Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018 May 15; 142(10): 2186−2187. doi: 10.1002/ijc.31231.Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018 May 15; 142(10): 2186−2187. doi: 10.1002/ijc.31231.Guo F, Cofie L E, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018 Aug; 55(2): 197−204. doi: 10.1016/j.amepre.2018.03.013.Guo F, Cofie L E, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018 Aug; 55(2): 197−204. doi: 10.1016/j.amepre.2018.03.013.Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One. 2013 Aug 29; 8(8): e72088. doi: 10.1371/journal.pone.0072088. eCollection 2013.Vänskä S, Auranen K, Leino T, et al. Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach. PLoS One. 2013 Aug 29; 8(8): e72088. doi: 10.1371/journal.pone.0072088. eCollection 2013.Bruni, L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul; 4(7): e453−63. doi: 10.1016/S2214-109X(16)30099-7.Bruni, L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016 Jul; 4(7): e453−63. doi: 10.1016/S2214-109X(16)30099-7.Drolet M, Bénard É, Pérez N, et al. M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Jun 26. pii: S0140-6736(19): 30298−3. doi: 10.1016/S0140-6736(19)30298-3.Drolet M, Bénard É, Pérez N, et al. M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019 Jun 26. pii: S0140-6736(19): 30298−3. doi: 10.1016/S0140-6736(19)30298-3.Lehtinen M, Luostarinen T, Vänskä S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomised (III). Int J Cancer. 2018 Nov 1; 143(9): 2299−2310. doi: 10.1002/ijc.31618.Lehtinen M, Luostarinen T, Vänskä S, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomised (III). Int J Cancer. 2018 Nov 1; 143(9): 2299−2310. doi: 10.1002/ijc.31618.Lehtinen M, Baussano I, Paavonen J, et al. Eradication of human papillomavirus and elimination of HPV-related diseases − scientific basis for global public health policies. Expert Rev Vaccines. 2019 Feb; 18(2): 153−160. doi: 10.1080/14760584.2019.1568876.Lehtinen M, Baussano I, Paavonen J, et al. Eradication of human papillomavirus and elimination of HPV-related diseases − scientific basis for global public health policies. Expert Rev Vaccines. 2019 Feb; 18(2): 153−160. doi: 10.1080/14760584.2019.1568876.Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and metaanalysis of predictions from transmission-dynamic models. Lancet Public Health. 2016 Nov; 1(1): e8−e17. doi: 10.1016/S2468-2667(16)30001-9.Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and metaanalysis of predictions from transmission-dynamic models. Lancet Public Health. 2016 Nov; 1(1): e8−e17. doi: 10.1016/S2468-2667(16)30001-9.Elfström KM, Lazzarato F, Franceschi S, et al. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016 Jan 15; 213(2): 199−205. doi: 10.1093/infdis/jiv368.Elfström KM, Lazzarato F, Franceschi S, et al. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016 Jan 15; 213(2): 199−205. doi: 10.1093/infdis/jiv368.Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust 2016; 205: 359–64.Smith M, Canfell K. Impact of the Australian National Cervical Screening Program in women of different ages. Med J Aust 2016; 205: 359–64.Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Dec 4, 2017. Доступно на: http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Dec 4, 2017. Available at: http://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians. Oct 8, 2017. Доступно на: http://parlinfo.aph.gov.au/parlInfo/search/display/display.w3p;query=Id%3A%22media%2Fpressrel%2F5562151%22.Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians. Oct 8, 2017. Available at: http://parlinfo.aph.gov.au/parlInfo/search/display/display.w3p;query=Id%3A%22media%2Fpressrel%2F5562151%22.Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019 Jan; 4(1): e19−e27. doi: 10.1016/S2468-2667(18)30183-X.Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019 Jan; 4(1): e19−e27. doi: 10.1016/S2468-2667(18)30183-X.

The authors declare that there are no conflicts of interest present.